From Greg Peterson, CEO
Those of us who live with Type 1 Diabetes have benefitted from a century of considerable improvement in the tools needed to effectively manage our T1D. However, much remains to be done. In the early 1990s, we learned definitively that excellent blood sugar control offered protection from the dreaded long-term complications of diabetes. Since that time, patients have been challenged by a fundamentally simple equation:
Excellent blood glucose control = Safety from long-term complications
Excellent blood glucose control is defined as achieving and maintaining an A1C of 7% or lower while avoiding hypoglycemia. Sadly, fewer than 15% of us manage to achieve this goal, and this realization has led to an increasing acceptance within the professional diabetes community of two critically important concepts:
1) Our current tools and management strategies have failed to adequately meet the needs of those of us who live with diabetes day-to-day in the real world. A recent large-scale study clearly demonstrates this and further suggests that the trend in improving A1C results has plateaued and may be reversing.
2) There is a rapidly growing awareness among physicians and scientists within the diabetes community that intraperitoneal insulin delivery is far superior to subcutaneous insulin delivery and is the “missing link” that will enable patients to achieve excellent glycemic control, with far less difficulty and greatly reduced risk of hypoglycemia. Most importantly, it will allow us to develop a truly autonomous “artificial pancreas”.
I, and more than three hundred others who live with T1D, have experienced first-hand that this is true, as we live with an implantable insulin pump that delivers insulin intraperitoneally. Words fail to convey the dramatic improvement in our quality of life – none of us is willing to give it up.
Unfortunately, the world’s only implantable insulin pump is severely outdated, relying upon technology from the 1990s. Further, it will no longer be manufactured as of mid-2020.
The mission of PhysioLogic Devices is to develop a modern and affordable implantable insulin pump linked to the most advanced continuous glucose sensor available, controlled by a simple and safe insulin delivery algorithm – a truly autonomous glucose control system that will completely remove the management burden of living with diabetes.
I am exceedingly fortunate to have experienced and benefitted from an implantable insulin pump for the past 27 years, despite its current technological limitations. I now have the privilege of managing a company uniquely qualified to take the next step – bringing truly life-changing technology to millions of T1Ds worldwide.